Time filter

Source Type

Le Touquet – Paris-Plage, France

Garabedian M.,Hopital Saint Vincent de Paul
OCL - Oleagineux Corps Gras Lipides

Besides its well known anti-rachitic properties, vitamin D has numerous in vitro and in vivo actions on the proliferation-differentiation of epidermal and cancer cells, as well as on the recruitment, differentiation and activities of the immune cells. Even though numerous association studies have suggested a possible link between a low vitamin D status and the risk of developing tumoral, auto-immune, neurologic or cardiovascular diseases, further data have proven to be more discordant and at best modest. In addition, the range of vitamin D doses or status active on these extra-skeletal pathologies remains poorly defined, between insufficiency and overload. Looking forward to clearly needed randomized intervention studies, optimal vitamin D status and intakes remain best defined on the basis of the vitamin D indisputable effects on calcium homeostasis and skeletal mineralization. Source

Diana J.,Hopital Saint Vincent de Paul
Discovery medicine

Type 1 diabetes (T1D) is a complex autoimmune disease that is untimely caused by the destruction of insulin-producing pancreatic β-cells by autoreactive T cells. The development of the pathology involved several cell types of both the innate and adaptive immune systems. This disease is under the control of several genetic loci of susceptibility but it is also influenced by environmental factors such as infectious agents. Studies in animal models, such as the non-obese diabetic (NOD) mouse, reveal that during the development of T1D multiple interactions occur between macrophages, dendritic cells (DC), natural killer (NK) cells, NKT cells, and lymphocytes. As a consequence, the various components of the immune system can be of peculiar interest as therapeutic targets for disease prevention or cure. This review focuses on the involvement of innate immune cells in the development and the prevention of T1D. Source

Bonneau N.,CNRS Mechanical Adaptation and Evolution | Simonis C.,CNRS Mechanical Adaptation and Evolution | Seringe R.,Hopital Saint Vincent de Paul | Tardieu C.,CNRS Mechanical Adaptation and Evolution
American Journal of Physical Anthropology

The developing fetus is protected from external environmental influences by maternal tissues. However, these structures have a limited elasticity, such that the fetus must grow in a confined space, constraining its size at the end of pregnancy. Can these constraints modify the morphology of the fetal skeleton? The intensity of these constraints increases between 5 months and birth, making it the most appropriate period to address this question. A sample of 89 fetal femora was analyzed, and results provide evidence that during this period, the torsion of the femoral shaft (quantified by means of a new three-dimensional method) increases gradually. Two explanations were considered: this increase could signal effects of constraints induced by the intrauterine cavity, developmental patterning, or some combination of these two. Different arguments tend to support the biomechanical explanation, rather than a programming pattern formation. Indeed, the identification of the femur as a first degree lever, created by the hyperflexion of the fetal lower limbs on the pelvis, could explain the increase in femoral shaft torsion during prenatal life. A comparison with femora of infants is in accordance with this mechanical interpretation, which is possible through bone modeling/remodeling. Although genetic and epigenetic mechanisms may regulate timing of fetal development, our data suggest that at birth, the fetal skeleton also has an intrauterine mechanical history through adaptive bone plasticity. Copyright © 2011 Wiley-Liss, Inc. Source

Gattermann N.,Heinrich Heine University Dusseldorf | Finelli C.,Policlinico S. Orsola Malpighi | Porta M.D.,IRCCS Policlinico S. Matteo | Fenaux P.,University Paris - Sud | And 9 more authors.

Background Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on there reductions/improvements have been limited to case reports and small studies. Design and Methods To explore this observation in a large population of patients, we report a post-hoc analysis evaluating hematologic response to deferasirox in a cohort of iron-overloaded patients with myelodysplastic syndromes enrolled in the Evaluation of Patients' Iron Chelation with Exjade® (EPIC) study using International Working Group 2006 criteria. Results Two-hundred and forty-seven, 100 and 50 patients without concomitant medication for myelodysplastic syndromes were eligible for analysis of erythroid, platelet and neutrophil responses, respectively. Erythroid, platelet and neutrophil responses were observed in 21.5% (53/247), 13.0% (13/100) and 22.0% (11/50) of the patients after a median of 109, 169 and 226 days, respectively. Median serum ferritin reductions were greater in hematologic responders compared with non-responders at end of study, although these differences were not statistically significant. A reduction in labile plasma iron to less than 0.4 μmol/L was observed from week 12 onwards; this change did not differ between hematologic responders and non-responders. Conclusions This analysis suggests that deferasirox treatment for up to 1 year could lead to improvement in hematologic parameters in some patients with myelodysplastic syndromes. ©2012 Ferrata Storti Foundation. Source

Querques G.,University Paris Est Creteil | Querques G.,Vita-Salute San Raffaele University | Tran T.H.C.,Hopital Saint Vincent de Paul | Forte R.,University Paris Est Creteil | And 3 more authors.
Graefe's Archive for Clinical and Experimental Ophthalmology

Background To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections. Methods We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months. Results Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8±7.3 years) were included. Mean follow-up was 20.3±6.2 months. During the first 12 months, patients received 5.5±2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters, p=0.04), and stabilized at 12-month visit (55.7 ±18.2 letters; p=0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 ±54.7 ?m vs 281.0 ±61.3 ?m at baseline, p=0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27±3.9 mm 2 at baseline vs 4.60±3.5 mm 2 at month 12, p=0.4), and greatest linear dimension (GLD 2.66± 1.2 mm at baseline vs 2.55±1.0 mm at month 12, p=0.3). Eight eyes (15.7%) showed CNV growth on ICGA (lesion area 3.98±3.2 mm2 at baseline vs 4.3±2.7 mm2 at month-12, p=0.6; GLD 2.11±1.0 mm at baseline vs 2.70±0.8 mm at month-12, p=0.05). Conclusion ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression. © 2011 Springer-Verlag. Source

Discover hidden collaborations